Prevalence of self-perceived audiovestibular symptoms in Egyptian COVID-19 patients.
Audiovestibular symptoms
COVID-19
Ear fullness
Hearing loss
Tinnitus
Vertigo
Journal
The Journal of the Egyptian Public Health Association
ISSN: 0013-2446
Titre abrégé: J Egypt Public Health Assoc
Pays: United States
ID NLM: 7505602
Informations de publication
Date de publication:
18 Sep 2023
18 Sep 2023
Historique:
received:
15
12
2022
accepted:
17
08
2023
medline:
18
9
2023
pubmed:
18
9
2023
entrez:
17
9
2023
Statut:
epublish
Résumé
According to National Institute for Health and Care Excellence (NICE), UK, common audiovestibular symptoms of COVID-19 include dizziness, tinnitus, and otalgia. The pathogenesis of otologic disorders ranges from direct damage to the inner ear structures to immune-mediated damage. Since the start of the pandemic, the prevalence of audiovestibular symptoms linked to COVID-19 has not been thoroughly investigated in Egypt. Our objective is to study and analyze the prevalence of the audiovestibular symptoms in the Egyptian population with history of COVID-19 infection. A cross-sectional study was conducted among Egyptian adults on the presence and nature of the audiovestibular manifestations in COVID-19 patients. An online questionnaire was used. The questionnaire was developed using Google Form. It was disseminated to the target population through social platforms from October 2021 till February 2022. Data from 245 respondents were collected through online assessment of a convenient sample. The following de novo audiovestibular symptoms were experienced by the participants: Vertigo 20.8%, hearing loss 13.9%, tinnitus 12.7% and ear fullness 11.4%. No correlation was found between the investigations done (D-Dimer, CT chest) and the audiovestibular symptoms. Audiovestibular symptoms are fairly common among COVID-19 patients, with higher prevalence, particularly of vertigo, in our study sample compared to the literature. It is recommended that patients with audiovestibular symptoms undergo early testing so that prompt interventions can be taken.
Sections du résumé
BACKGROUND
BACKGROUND
According to National Institute for Health and Care Excellence (NICE), UK, common audiovestibular symptoms of COVID-19 include dizziness, tinnitus, and otalgia. The pathogenesis of otologic disorders ranges from direct damage to the inner ear structures to immune-mediated damage. Since the start of the pandemic, the prevalence of audiovestibular symptoms linked to COVID-19 has not been thoroughly investigated in Egypt. Our objective is to study and analyze the prevalence of the audiovestibular symptoms in the Egyptian population with history of COVID-19 infection.
METHODS
METHODS
A cross-sectional study was conducted among Egyptian adults on the presence and nature of the audiovestibular manifestations in COVID-19 patients. An online questionnaire was used. The questionnaire was developed using Google Form. It was disseminated to the target population through social platforms from October 2021 till February 2022.
RESULTS
RESULTS
Data from 245 respondents were collected through online assessment of a convenient sample. The following de novo audiovestibular symptoms were experienced by the participants: Vertigo 20.8%, hearing loss 13.9%, tinnitus 12.7% and ear fullness 11.4%. No correlation was found between the investigations done (D-Dimer, CT chest) and the audiovestibular symptoms.
CONCLUSION
CONCLUSIONS
Audiovestibular symptoms are fairly common among COVID-19 patients, with higher prevalence, particularly of vertigo, in our study sample compared to the literature. It is recommended that patients with audiovestibular symptoms undergo early testing so that prompt interventions can be taken.
Identifiants
pubmed: 37718344
doi: 10.1186/s42506-023-00143-7
pii: 10.1186/s42506-023-00143-7
pmc: PMC10505598
doi:
Types de publication
Journal Article
Langues
eng
Pagination
18Informations de copyright
© 2023. Egyptian Public Health Association.
Références
Semin Hear. 2012 Aug;33(3):242-250
pubmed: 25346568
Audiol Neurootol. 2022;27(4):297-311
pubmed: 35240596
J Immunol Res. 2014;2014:459048
pubmed: 24741601
Trends Hear. 2014 Jul 29;18:
pubmed: 25080364
BMJ Case Rep. 2020 Sep 16;13(9):
pubmed: 32938654
Am J Otolaryngol. 2020 Sep - Oct;41(5):102612
pubmed: 32574896
Nat Rev Cardiol. 2022 Jul;19(7):475-495
pubmed: 35027697
Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):3092-3097
pubmed: 34422621
J Vestib Res. 2021;31(5):381-387
pubmed: 33579886
Eur J Clin Invest. 2003 Dec;33(12):1045-50
pubmed: 14636287
Cureus. 2020 Nov 28;12(11):e11752
pubmed: 33403182
Cureus. 2020 Jun 30;12(6):e8918
pubmed: 32760619
J Neurol. 2020 Jul;267(7):1896-1905
pubmed: 30923934
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Int J Audiol. 2022 Oct;61(10):832-840
pubmed: 34370603
Front Neurol. 2022 Mar 18;13:850337
pubmed: 35370886
Eur Arch Otorhinolaryngol. 2020 Jun;277(6):1609-1616
pubmed: 32078026
Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):3036-3042
pubmed: 34277385
Laryngoscope. 2021 Jun;131(6):E2013-E2017
pubmed: 33296096
JAMA Otolaryngol Head Neck Surg. 2020 Oct 1;146(10):964-966
pubmed: 32701126
Eur Arch Otorhinolaryngol. 2021 Oct;278(10):3725-3730
pubmed: 33095432
Int J Audiol. 2020 Jul;59(7):487-491
pubmed: 32530326
Egypt J Neurol Psychiatr Neurosurg. 2023;59(1):65
pubmed: 37200583
PLoS One. 2022 Jul 19;17(7):e0269185
pubmed: 35852999
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375
Am J Otolaryngol. 2020 May - Jun;41(3):102483
pubmed: 32307189
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
Front Neurol. 2021 Aug 04;12:707207
pubmed: 34421805